Evidence map›Paper›PMID 40238098›Full record

ArticleJAMA network open2025

Polygenic Scores and Mood Disorder Onsets in the Context of Family History and Early Psychopathology.

Kathryn Freeman, Alyson Zwicker, Janice M Fullerton, Danella M Hafeman, Neeltje E M van Haren, John Merranko, Benjamin I Goldstein, Emma K Stapp, Elena de la Serna, Dolores Moreno and 20 more

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Kathryn FreemanDepartment of Medical Neuroscience, Dalhousie University, Halifax, Nova Scotia, Canada.
Alyson ZwickerNova Scotia Health Authority, Halifax, Nova Scotia, Canada.
Janice M FullertonNeuroscience Research Australia, Randwick, New South Wales, Australia.
Danella M HafemanWestern Psychiatric Hospital, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Neeltje E M van HarenDepartment of Child and Adolescent Psychiatry/Psychology, Erasmus University Medical Center, Sophia Children's Hospital, Rotterdam, the Netherlands.
John MerrankoWestern Psychiatric Hospital, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Benjamin I GoldsteinCentre for Addiction and Mental Health, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Emma K StappMilken Institute School of Public Health, George Washington University, Washington, District of Columbia.
Elena de la SernaFundacio Clínic per la Recerca Biomedica, Institut d'Investigacions Biomèdiques d'August Pi i Sunye, Barcelona, Spain.
Dolores MorenoCentro de Investigación Biomédica en Red de Salud Mental, Madrid, Spain.
Gisela SugranyesFundacio Clínic per la Recerca Biomedica, Institut d'Investigacions Biomèdiques d'August Pi i Sunye, Barcelona, Spain.
Sergi MasFundacio Clínic per la Recerca Biomedica, Institut d'Investigacions Biomèdiques d'August Pi i Sunye, Barcelona, Spain.
Gloria RobertsDiscipline of Psychiatry and Mental Health, School of Clinical Medicine, University of New South Wales, Randwick, New South Wales, Australia.
Claudio TomaNeuroscience Research Australia, Randwick, New South Wales, Australia.
Peter R SchofieldNeuroscience Research Australia, Randwick, New South Wales, Australia.
Howard J EdenbergDepartment of Biochemistry and Molecular Biology, Indiana University, Indianapolis.
Holly C WilcoxJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Melvin G McInnisDepartment of Psychiatry, University of Michigan, Ann Arbor.
Lukas PropperDepartment of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
Barbara PavlovaNova Scotia Health Authority, Halifax, Nova Scotia, Canada.
Samuel A StewartDepartment of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.
Eileen M Denovan-WrightDepartment of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada.
Guy A RouleauMontreal Neurological Institute and Department of Neurology, McGill University, Montreal, Quebec, Canada.
Josefina Castro-FornielesFundacio Clínic per la Recerca Biomedica, Institut d'Investigacions Biomèdiques d'August Pi i Sunye, Barcelona, Spain.
Manon H J HillegersDepartment of Child and Adolescent Psychiatry/Psychology, Erasmus University Medical Center, Sophia Children's Hospital, Rotterdam, the Netherlands.
Boris BirmaherWestern Psychiatric Hospital, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Philip B MitchellDiscipline of Psychiatry and Mental Health, School of Clinical Medicine, University of New South Wales, Randwick, New South Wales, Australia.
Martin AldaNova Scotia Health Authority, Halifax, Nova Scotia, Canada.
John I NurnbergerDepartment of Psychiatry, Indiana University School of Medicine, Indianapolis.
Rudolf UherDepartment of Medical Neuroscience, Dalhousie University, Halifax, Nova Scotia, Canada.

Funding

Adolescents at High Risk for Familial Bipolar DisorderR01MH068009 · NIMH · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI NURNBERGER, JOHN I · 2005 to 2009
$1.7M
Adolescents at High Risk for Familial Bipolar Disorder.R01MH068006 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MCINNIS, MELVIN G · 2005 to 2009
$1.4M
Adolescents at High Risk For Familial Bipolar DisorderR01MH073151 · NIMH · WASHINGTON UNIVERSITY · PI GLOWINSKI, ANNE L · 2005 to 2009
$1.3M
CIHRNIMH NIH HHS R01 MH068006NIMH NIH HHS R01 MH068009NIMH NIH HHS R01 MH073151
6 · The paper itself

Abstract

Importance: Bipolar disorder (BD) and major depressive disorder (MDD) aggregate within families, with risk often first manifesting as early psychopathology, including attention-deficit/hyperactivity disorder (ADHD) and anxiety disorders. Objective: To determine whether polygenic scores (PGS) are associated with mood disorder onset independent of familial high risk for BD (FHR-BD) and early psychopathology. Design, Setting, and Participants: This cohort study used data from 7 prospective cohorts enriched in FHR-BD from Australia, Canada, the Netherlands, Spain, and the US. Participants with FHR-BD, defined as having at least 1 first-degree relative with BD, were compared with participants without FHR for any mood disorder. Participants were repeatedly assessed with variable follow-up intervals from July 1992 to July 2023. Data were analyzed from August 2023 to August 2024. Exposures: PGS indexed genetic liability for MDD, BD, anxiety, neuroticism, subjective well-being, ADHD, self-regulation, and addiction risk factor. Semistructured diagnostic interviews with relatives established FHR-BD. ADHD or anxiety disorder diagnoses before mood disorder onset constituted early psychopathology. Main Outcomes and Measures: The outcome of interest, mood disorder onset, was defined as a consensus-confirmed new diagnosis of MDD or BD. Cox regression examined associations of PGS, FHR-BD, ADHD, and anxiety with mood disorder onset. Kaplan-Meier curves and log-rank tests evaluated the probability of onset by PGS quartile and familial risk status. Results: A total of 1064 participants (546 [51.3%] female; mean [SD] age at last assessment, 21.7 [5.1] years), including 660 with FHR-BD and 404 without FHR for any mood disorder, were repeatedly assessed for mental disorders. A total of 399 mood disorder onsets occurred over a variable mean (SD) follow-up interval of 6.3 (5.7) years. Multiple PGS were associated with onset after correcting for FHR-BD and early psychopathology, including PGS for ADHD (hazard ratio [HR], 1.19; 95% CI, 1.06-1.34), self-regulation (HR, 1.19; 95% CI, 1.06-1.34), neuroticism (HR, 1.18; 95% CI, 1.06-1.32), MDD (HR, 1.17; 95% CI, 1.04-1.31), addiction risk factor (HR, 1.16; 95% CI, 1.04-1.30), anxiety (HR, 1.15; 95% CI, 1.02-1.28), BD (HR, 1.14; 95% CI, 1.02-1.28), and subjective well-being (HR, 0.89; 95% CI, 0.79-0.99). High PGS for addiction risk factor, anxiety, BD, and MDD were associated with increased probability of onset in the control group. High PGS for ADHD and self-regulation increased rates of onset among participants with FHR-BD. PGS for self-regulation, ADHD, and addiction risk factors showed stronger associations with onsets of BD than MDD. Conclusions and Relevance: In this cohort study, multiple PGS were associated with mood disorder onset independent of family history of BD and premorbid diagnoses of ADHD or anxiety. The association between PGS and mood disorder risk varied depending on family history status.

Indexed as

Bipolar DisorderMajor Depressive DisorderMood DisordersMultifactorial InheritanceAdultAnxiety DisordersAttention Deficit Disorder with HyperactivityAustraliaFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedNetherlandsProspective StudiesPsychopathology

Identifiers

PMID40238098
PMCPMC12004201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.